Pharmacokinetics of deramciclane in dogs after single oral and intravenous dosing and multiple oral dosing

Biopharmaceutics and Drug Disposition

Volumn 19, Issue 8, 1998, Pages 531-539

  Kanerva, Harri ^a   Huuskonen, Hannele ^b   Alhonen Raatesalmi, Anneli ^a   Nevalainen, Timo ^c   Urtti, Arto ^c  

^a ORION CORPORATION   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Clearance; Deramciclane fumarate; Dog; Non linear pharmacokinetics

Indexed keywords

DERAMCICLANE FUMARATE; DRUG METABOLITE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; GASTROINTESTINAL ABSORPTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; BORNANES; DEALKYLATION; DOGS; HALF-LIFE; INJECTIONS, INTRAVENOUS;

EID: 0031770536     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(1998110)19:8<531::AID-BDD135>3.0.CO;2-I     Document Type: Article

References (23)

1. C.B. Taylor, Treatment of Anxiety Disorders. In Textbook of Psychopharmacology, A.F. Schatzberg and C.B. Nemeroff (Eds), American Psychiatric Press, Washington DC, 1995, pp. 641-656.
2. 2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr. Scand., 83, 244-248 (1991).
3. A. Reyntjens, Y.G. Gelders, M-L.J.A. Hoppenbouers and G. Van den Bussche, Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Dev. Res., 8, 205-211 (1986).
4. D.S. Goldbloom and M. Polmsted, Pharmacotherapy of bulimia nervosa enclosed with fluoxetine: assessment of clinically significant attitudinal change. Am. J. Psychiatr., 150(5), 770-774 (1993).
5. N.T.R. Burrows, F.K. Judd and I.M. McIntyre, Serotonin and panic disorders: a review of clinical studies. Int. J. Clin. Pharm. Res., IX(2), 151-157 (1989).
6. A.L. Nyth, C.G. Gottfries, K. Lyby, L. Smedegaard-Andersen, J. Glynding-Sabroe, M. Kristensen, H-E. Refsum, E. Öfsti, S. Eriksson and S. Syversen, A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr. Scand., 86, 138-145 (1992).
7. T.T.A. Tamminen and V.V. Lehtinen, A double-blind parallel study to compare fluoxetine with doxepin in the treatment of major depressive disorders. Int. Clin. Psychopharmacol., 4, 51-56 (1989).
8. I. Gacsalyi, E. Schmidt, I. Gyertyan, E. Vasar, A. Lang, A. Haapalinna, M. Fekete, J. Hietala, E. Syvälahti, P. Tuomainen and P.T. Männistö, Receptor binding profile and anxiolytic-type activity of deramciclane (EGIS-3886) in animal models. Drug Dev. Res., 40, 333-348 (1997).
9. 2C receptor down-regulation when administered chronically. Psychopharmacology, 136, 99-104 (1998).
10. 2 receptors. Pharm. Pharmacol. Lett., 6, 82-85 (1996).
11. S.J. Peroutka, Serotonin receptor subtypes. Their evolution and clinical relevance. CNS Drugs, 4(Suppl 1), 18-28 (1995).
12. E. Bojti, J. Leibinger, G. Grezal and I. Klebovich, Pharmacokinetics of deramciclane in dogs. Pharm. Sci., 3, 503-506 (1997).
13. K.B. Nemes, M. Abermann, E. Bojti and I. Klebovich, A highly sensitive gc method for the determination of deramciclane and its N-desmethyl metabolite rat and dog plasma. In Biofluid Assay for Peptide-related and Other Drugs, Methodological Surveys in Bioanalysis of Drugs, vol 24, E. Reid, H.M. Hill and I.D. Wilson (Eds), The Royal Society of Chemistry, Cambridge, UK, 1996, pp. 103-104.
14. R. Gomeni and C. Gomeni, IGPHARM: interactive graphic package for pharmacokinetic analysis. Comp. Biomed. Res., 11, 345-361 (1978).
15. W.A. Richel, Drug metabolism. In Handbook of Basic Pharmacokinetics Including Clinical Applications, 3rd ed., W.A. Richel (Ed.), Drug Inteligence Publications, Hamilton, IL, 1986, 142-167 (1986).
16. M. Rowland and T.N. Tozer, Elimination. In Clinical Pharmacokinetics: Concepts and Applications, 3rd ed., D. Balado (Ed.), Williams and Wilkins, Philadelphia, PA, 1995, pp. 156-183.
17. J. Lengyel, A. Bolehovsky and I. Klebovich, M. Aberman and K. Magyar, Absorption of a new anxiolytic compound deramciclane in rats, dogs and rabbits. Arzneim. Forsch./Drug Res. (1998).
18. V.J. Wacher, L. Salphati and L.Z. Benet, Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev., 20(1), 99-112 (1996).
19. M. Patfalusi, I. Hazai and I. Klebovich, Fate of radiolabelled deramciclane (EGIS-3886) in rats, pharmacokinetics, excretion and separation of potential metabolites. ISSX Proc., 11, 131 (1997).
20. I. Hazai, I. Urmos and I. Klebovich, Application of TLC-Digital autoradiography as a rapid method in a pilot study of deramciclane metabolism. J. Planar. Chromatogr., 8, 92-97 (1995).
21. C.V. Greenway and R.D. Stark, Hepatic vascular bed. Physiol Rev., 51, 23-65 (1971).
22. J. Visy, I. Fitos, G. Mady, M. Simonyi and I. Klebovich, Plasma protein binding of deramciclane in different species. Pharm. Sci., 2, 315-318 (1996).
23. Egis Pharmaceuticals, Cardiovascular Effects in Anaesthetized Dogs, Internal Study Report, 1994.